Loading…
Pharmaceutical Studies of Levothyroxine Sodium Hydrate Suppository Provided as a Hospital Preparation
The levothyroxine sodium hydrate suppository (L-T4-suppository) is provided as a hospital preparation for the treatment of hypothyroid patients with dysphagia in Japan because only oral preparations of levothyroxine sodium (L-T4) are approved for the treatment of hypothyroidism. However, it has been...
Saved in:
Published in: | Biological & pharmaceutical bulletin 2015/04/01, Vol.38(4), pp.625-628 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353 |
---|---|
cites | cdi_FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353 |
container_end_page | 628 |
container_issue | 4 |
container_start_page | 625 |
container_title | Biological & pharmaceutical bulletin |
container_volume | 38 |
creator | Hamada, Yuhei Masuda, Kazushi Okubo, Masato Nakasa, Hiromitsu Sekine, Yuko Ishii, Itsuko |
description | The levothyroxine sodium hydrate suppository (L-T4-suppository) is provided as a hospital preparation for the treatment of hypothyroid patients with dysphagia in Japan because only oral preparations of levothyroxine sodium (L-T4) are approved for the treatment of hypothyroidism. However, it has been found that serum thyroxine and triiodothyronine levels do not increase as expected with the hospital preparation, requiring a higher dosage of L-T4 in the L-T4-suppository than in the oral preparations. In this study, to determine an effective thyroid gland hormone-replacement therapy for patients with dysphagia, the pharmaceutical properties of the L-T4-suppository were investigated. Suppositories containing 300 µg L-T4 in a base of Witepsol H-15 and Witepsol E-75 (ratio of 1 : 1) were prepared according to Chiba University Hospital’s protocol. Content uniformity, stability, and suppository release were tested. The L-T4-suppository had uniform weight and content. The content and release property were stable over 90 d when the L-T4-suppository was stored at 4°C and protected from light. The release rate of L-T4 increased as pH increased. However, no L-T4 was released below pH 7.2. The release rate of L-T4 decreased as temperature decreased. These findings suggest that the low level of release of L-T4 in the rectum under physiological conditions may be the cause of the low serum thyroxine and triiodothyronine levels following L-T4-suppository administration. |
doi_str_mv | 10.1248/bpb.b14-00721 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1669833170</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1669833170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353</originalsourceid><addsrcrecordid>eNpdkU2LFDEQhoMo7rh69CoNXrz0mo9OJ32UQXeEAQdWzyEf1W6Gnk6bdC_Ov7dmZx3BS4VQD28VTxHyltEbxhv90U3uxrGmplRx9oysmGhULTmTz8mKdkzXLZP6irwqZU-RoVy8JFdcasHbRqwI7O5tPlgPyxy9Haq7eQkRSpX6agsPab4_5vQ7jlDdpRCXQ7U5hmxn_C7TlEqcUz5Wu5weYoBQ2VLZapPKFGeM2mWYLMIxja_Ji94OBd48vdfkx5fP39ebevvt9uv607b2uNhcd9q6znPNg3NN33sJjErtlbaBCceZVW3Xg2hbR70MVADtQxs4B66gD0KKa_LhnDvl9GuBMptDLB6GwY6QlmJY23ZaCKYoou__Q_dpySNuZ5iSQkolOoVUfaZ8TqVk6M2U48Hmo2HUnPwb9G_Qv3n0j_y7p9TFHSBc6L_CEbg9A9g9CU_jgHb_zfZFuZiGZDhlEkOFppjNtKEtl6eieSMa1nWYtD4n7ctsf8JllM14yQEeFxPaNKdyWfDS9Xh2A6P4AzB5sJo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1753557397</pqid></control><display><type>article</type><title>Pharmaceutical Studies of Levothyroxine Sodium Hydrate Suppository Provided as a Hospital Preparation</title><source>Free Full-Text Journals in Chemistry</source><creator>Hamada, Yuhei ; Masuda, Kazushi ; Okubo, Masato ; Nakasa, Hiromitsu ; Sekine, Yuko ; Ishii, Itsuko</creator><creatorcontrib>Hamada, Yuhei ; Masuda, Kazushi ; Okubo, Masato ; Nakasa, Hiromitsu ; Sekine, Yuko ; Ishii, Itsuko ; University Hospital ; aDepartment of Practical Pharmacy ; cDivision of Pharmacy ; Graduate School of Pharmaceutical Sciences ; Chiba University ; Faculty of Pharmaceutical Sciences ; bDepartment of Practical Pharmacy ; and (dDepartment of Clinical Pharmacology ; Chiba University School of Medicine</creatorcontrib><description>The levothyroxine sodium hydrate suppository (L-T4-suppository) is provided as a hospital preparation for the treatment of hypothyroid patients with dysphagia in Japan because only oral preparations of levothyroxine sodium (L-T4) are approved for the treatment of hypothyroidism. However, it has been found that serum thyroxine and triiodothyronine levels do not increase as expected with the hospital preparation, requiring a higher dosage of L-T4 in the L-T4-suppository than in the oral preparations. In this study, to determine an effective thyroid gland hormone-replacement therapy for patients with dysphagia, the pharmaceutical properties of the L-T4-suppository were investigated. Suppositories containing 300 µg L-T4 in a base of Witepsol H-15 and Witepsol E-75 (ratio of 1 : 1) were prepared according to Chiba University Hospital’s protocol. Content uniformity, stability, and suppository release were tested. The L-T4-suppository had uniform weight and content. The content and release property were stable over 90 d when the L-T4-suppository was stored at 4°C and protected from light. The release rate of L-T4 increased as pH increased. However, no L-T4 was released below pH 7.2. The release rate of L-T4 decreased as temperature decreased. These findings suggest that the low level of release of L-T4 in the rectum under physiological conditions may be the cause of the low serum thyroxine and triiodothyronine levels following L-T4-suppository administration.</description><identifier>ISSN: 0918-6158</identifier><identifier>EISSN: 1347-5215</identifier><identifier>DOI: 10.1248/bpb.b14-00721</identifier><identifier>PMID: 25832643</identifier><language>eng</language><publisher>Japan: The Pharmaceutical Society of Japan</publisher><subject>Drug Compounding ; Drug Liberation ; Drug Stability ; Drug Storage ; hospital preparation ; hypothyroidism ; levothyroxine sodium hydrate ; Light ; pharmaceutical study ; Pharmacy Service, Hospital ; Suppositories ; suppository ; Temperature ; thyroid gland hormone replacement therapy ; Thyroxine - analysis ; Thyroxine - chemistry ; Triglycerides - chemistry</subject><ispartof>Biological and Pharmaceutical Bulletin, 2015/04/01, Vol.38(4), pp.625-628</ispartof><rights>2015 The Pharmaceutical Society of Japan</rights><rights>Copyright Japan Science and Technology Agency 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353</citedby><cites>FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25832643$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hamada, Yuhei</creatorcontrib><creatorcontrib>Masuda, Kazushi</creatorcontrib><creatorcontrib>Okubo, Masato</creatorcontrib><creatorcontrib>Nakasa, Hiromitsu</creatorcontrib><creatorcontrib>Sekine, Yuko</creatorcontrib><creatorcontrib>Ishii, Itsuko</creatorcontrib><creatorcontrib>University Hospital</creatorcontrib><creatorcontrib>aDepartment of Practical Pharmacy</creatorcontrib><creatorcontrib>cDivision of Pharmacy</creatorcontrib><creatorcontrib>Graduate School of Pharmaceutical Sciences</creatorcontrib><creatorcontrib>Chiba University</creatorcontrib><creatorcontrib>Faculty of Pharmaceutical Sciences</creatorcontrib><creatorcontrib>bDepartment of Practical Pharmacy</creatorcontrib><creatorcontrib>and (dDepartment of Clinical Pharmacology</creatorcontrib><creatorcontrib>Chiba University School of Medicine</creatorcontrib><title>Pharmaceutical Studies of Levothyroxine Sodium Hydrate Suppository Provided as a Hospital Preparation</title><title>Biological & pharmaceutical bulletin</title><addtitle>Biol Pharm Bull</addtitle><description>The levothyroxine sodium hydrate suppository (L-T4-suppository) is provided as a hospital preparation for the treatment of hypothyroid patients with dysphagia in Japan because only oral preparations of levothyroxine sodium (L-T4) are approved for the treatment of hypothyroidism. However, it has been found that serum thyroxine and triiodothyronine levels do not increase as expected with the hospital preparation, requiring a higher dosage of L-T4 in the L-T4-suppository than in the oral preparations. In this study, to determine an effective thyroid gland hormone-replacement therapy for patients with dysphagia, the pharmaceutical properties of the L-T4-suppository were investigated. Suppositories containing 300 µg L-T4 in a base of Witepsol H-15 and Witepsol E-75 (ratio of 1 : 1) were prepared according to Chiba University Hospital’s protocol. Content uniformity, stability, and suppository release were tested. The L-T4-suppository had uniform weight and content. The content and release property were stable over 90 d when the L-T4-suppository was stored at 4°C and protected from light. The release rate of L-T4 increased as pH increased. However, no L-T4 was released below pH 7.2. The release rate of L-T4 decreased as temperature decreased. These findings suggest that the low level of release of L-T4 in the rectum under physiological conditions may be the cause of the low serum thyroxine and triiodothyronine levels following L-T4-suppository administration.</description><subject>Drug Compounding</subject><subject>Drug Liberation</subject><subject>Drug Stability</subject><subject>Drug Storage</subject><subject>hospital preparation</subject><subject>hypothyroidism</subject><subject>levothyroxine sodium hydrate</subject><subject>Light</subject><subject>pharmaceutical study</subject><subject>Pharmacy Service, Hospital</subject><subject>Suppositories</subject><subject>suppository</subject><subject>Temperature</subject><subject>thyroid gland hormone replacement therapy</subject><subject>Thyroxine - analysis</subject><subject>Thyroxine - chemistry</subject><subject>Triglycerides - chemistry</subject><issn>0918-6158</issn><issn>1347-5215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNpdkU2LFDEQhoMo7rh69CoNXrz0mo9OJ32UQXeEAQdWzyEf1W6Gnk6bdC_Ov7dmZx3BS4VQD28VTxHyltEbxhv90U3uxrGmplRx9oysmGhULTmTz8mKdkzXLZP6irwqZU-RoVy8JFdcasHbRqwI7O5tPlgPyxy9Haq7eQkRSpX6agsPab4_5vQ7jlDdpRCXQ7U5hmxn_C7TlEqcUz5Wu5weYoBQ2VLZapPKFGeM2mWYLMIxja_Ji94OBd48vdfkx5fP39ebevvt9uv607b2uNhcd9q6znPNg3NN33sJjErtlbaBCceZVW3Xg2hbR70MVADtQxs4B66gD0KKa_LhnDvl9GuBMptDLB6GwY6QlmJY23ZaCKYoou__Q_dpySNuZ5iSQkolOoVUfaZ8TqVk6M2U48Hmo2HUnPwb9G_Qv3n0j_y7p9TFHSBc6L_CEbg9A9g9CU_jgHb_zfZFuZiGZDhlEkOFppjNtKEtl6eieSMa1nWYtD4n7ctsf8JllM14yQEeFxPaNKdyWfDS9Xh2A6P4AzB5sJo</recordid><startdate>20150401</startdate><enddate>20150401</enddate><creator>Hamada, Yuhei</creator><creator>Masuda, Kazushi</creator><creator>Okubo, Masato</creator><creator>Nakasa, Hiromitsu</creator><creator>Sekine, Yuko</creator><creator>Ishii, Itsuko</creator><general>The Pharmaceutical Society of Japan</general><general>Pharmaceutical Society of Japan</general><general>Japan Science and Technology Agency</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20150401</creationdate><title>Pharmaceutical Studies of Levothyroxine Sodium Hydrate Suppository Provided as a Hospital Preparation</title><author>Hamada, Yuhei ; Masuda, Kazushi ; Okubo, Masato ; Nakasa, Hiromitsu ; Sekine, Yuko ; Ishii, Itsuko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Drug Compounding</topic><topic>Drug Liberation</topic><topic>Drug Stability</topic><topic>Drug Storage</topic><topic>hospital preparation</topic><topic>hypothyroidism</topic><topic>levothyroxine sodium hydrate</topic><topic>Light</topic><topic>pharmaceutical study</topic><topic>Pharmacy Service, Hospital</topic><topic>Suppositories</topic><topic>suppository</topic><topic>Temperature</topic><topic>thyroid gland hormone replacement therapy</topic><topic>Thyroxine - analysis</topic><topic>Thyroxine - chemistry</topic><topic>Triglycerides - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hamada, Yuhei</creatorcontrib><creatorcontrib>Masuda, Kazushi</creatorcontrib><creatorcontrib>Okubo, Masato</creatorcontrib><creatorcontrib>Nakasa, Hiromitsu</creatorcontrib><creatorcontrib>Sekine, Yuko</creatorcontrib><creatorcontrib>Ishii, Itsuko</creatorcontrib><creatorcontrib>University Hospital</creatorcontrib><creatorcontrib>aDepartment of Practical Pharmacy</creatorcontrib><creatorcontrib>cDivision of Pharmacy</creatorcontrib><creatorcontrib>Graduate School of Pharmaceutical Sciences</creatorcontrib><creatorcontrib>Chiba University</creatorcontrib><creatorcontrib>Faculty of Pharmaceutical Sciences</creatorcontrib><creatorcontrib>bDepartment of Practical Pharmacy</creatorcontrib><creatorcontrib>and (dDepartment of Clinical Pharmacology</creatorcontrib><creatorcontrib>Chiba University School of Medicine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Biological & pharmaceutical bulletin</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hamada, Yuhei</au><au>Masuda, Kazushi</au><au>Okubo, Masato</au><au>Nakasa, Hiromitsu</au><au>Sekine, Yuko</au><au>Ishii, Itsuko</au><aucorp>University Hospital</aucorp><aucorp>aDepartment of Practical Pharmacy</aucorp><aucorp>cDivision of Pharmacy</aucorp><aucorp>Graduate School of Pharmaceutical Sciences</aucorp><aucorp>Chiba University</aucorp><aucorp>Faculty of Pharmaceutical Sciences</aucorp><aucorp>bDepartment of Practical Pharmacy</aucorp><aucorp>and (dDepartment of Clinical Pharmacology</aucorp><aucorp>Chiba University School of Medicine</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmaceutical Studies of Levothyroxine Sodium Hydrate Suppository Provided as a Hospital Preparation</atitle><jtitle>Biological & pharmaceutical bulletin</jtitle><addtitle>Biol Pharm Bull</addtitle><date>2015-04-01</date><risdate>2015</risdate><volume>38</volume><issue>4</issue><spage>625</spage><epage>628</epage><pages>625-628</pages><issn>0918-6158</issn><eissn>1347-5215</eissn><abstract>The levothyroxine sodium hydrate suppository (L-T4-suppository) is provided as a hospital preparation for the treatment of hypothyroid patients with dysphagia in Japan because only oral preparations of levothyroxine sodium (L-T4) are approved for the treatment of hypothyroidism. However, it has been found that serum thyroxine and triiodothyronine levels do not increase as expected with the hospital preparation, requiring a higher dosage of L-T4 in the L-T4-suppository than in the oral preparations. In this study, to determine an effective thyroid gland hormone-replacement therapy for patients with dysphagia, the pharmaceutical properties of the L-T4-suppository were investigated. Suppositories containing 300 µg L-T4 in a base of Witepsol H-15 and Witepsol E-75 (ratio of 1 : 1) were prepared according to Chiba University Hospital’s protocol. Content uniformity, stability, and suppository release were tested. The L-T4-suppository had uniform weight and content. The content and release property were stable over 90 d when the L-T4-suppository was stored at 4°C and protected from light. The release rate of L-T4 increased as pH increased. However, no L-T4 was released below pH 7.2. The release rate of L-T4 decreased as temperature decreased. These findings suggest that the low level of release of L-T4 in the rectum under physiological conditions may be the cause of the low serum thyroxine and triiodothyronine levels following L-T4-suppository administration.</abstract><cop>Japan</cop><pub>The Pharmaceutical Society of Japan</pub><pmid>25832643</pmid><doi>10.1248/bpb.b14-00721</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0918-6158 |
ispartof | Biological and Pharmaceutical Bulletin, 2015/04/01, Vol.38(4), pp.625-628 |
issn | 0918-6158 1347-5215 |
language | eng |
recordid | cdi_proquest_miscellaneous_1669833170 |
source | Free Full-Text Journals in Chemistry |
subjects | Drug Compounding Drug Liberation Drug Stability Drug Storage hospital preparation hypothyroidism levothyroxine sodium hydrate Light pharmaceutical study Pharmacy Service, Hospital Suppositories suppository Temperature thyroid gland hormone replacement therapy Thyroxine - analysis Thyroxine - chemistry Triglycerides - chemistry |
title | Pharmaceutical Studies of Levothyroxine Sodium Hydrate Suppository Provided as a Hospital Preparation |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A18%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmaceutical%20Studies%20of%20Levothyroxine%20Sodium%20Hydrate%20Suppository%20Provided%20as%20a%20Hospital%20Preparation&rft.jtitle=Biological%20&%20pharmaceutical%20bulletin&rft.au=Hamada,%20Yuhei&rft.aucorp=University%20Hospital&rft.date=2015-04-01&rft.volume=38&rft.issue=4&rft.spage=625&rft.epage=628&rft.pages=625-628&rft.issn=0918-6158&rft.eissn=1347-5215&rft_id=info:doi/10.1248/bpb.b14-00721&rft_dat=%3Cproquest_cross%3E1669833170%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c702t-98ab9c282dbb4ffc5e1058c78ad13b21a769fe366b0c5d03e0fd6d22e27efd353%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1753557397&rft_id=info:pmid/25832643&rfr_iscdi=true |